[ad_1]
The COVID-19 pandemic precipitated both political parties to wrap themselves in the banner of science, even those voters who historically were more inclined to oppose vaccines and medicines and to buy organic food.
They should have been in Team Science all along and a new analysis shows why; over a recent 16-year period, over 1.2 million people were saved thanks to 106 new treatments approved for these 15 most common cancers from 2000 to 2016 – including colorectal cancer, lung cancer, breast cancer , non-Hodgkin’s lymphoma, leukemia, melanoma, gastric cancer and kidney cancer.
The study used a number of national datasets from sources including the Centers for Disease Control and Prevention, the US Mortality Files from the National Center of Health Statistics, Survival, Epidemiology and End Results Program (SEER), and cancer of the United States.
That 1,291,769 mortality drop translated into a 24% reduction per 100,000 people in the United States. Some specific drops:
Breast Cancer – 127,874
Colorectal – 46.705
Lung – 375,256
Prostate – 476,210
Non-Hodgkin’s lymphoma – 48,836
Lead author, Dr Joanna MacEwan, of PRECISIONheor, says, “These findings may help better understand whether increased spending on anticancer drugs is worth the investment. Even if we don’t answer that question directly, ours are. results show that the result of the investment – the approval of new anticancer therapies – generates significant benefits for patients.
“The effectiveness of each treatment is estimated from clinical trial results, but this study provides evidence that survival gains measured in clinical trials are translating into real-world patient health benefits and confirms the research. which has also shown that new pharmaceutical treatments are associated with better survival outcomes for patients. “
Some cancers need to be addressed later
Although death rates have decreased in many cancers, estimated deaths have increased by 825 in people with thyroid cancer and by 7,768 in those with bladder cancer. But there weren’t many drug approvals during this time: five for thyroid cancer and three for bladder cancer. There were no approvals in liver or uterine cancer from 2000 to 2016 and few approvals in pancreatic and oral cancer.
Some are still embracing supplements and alternatives to science when it comes to vaccines, but we are likely back to the days of the Clinton administration, when the National Center for Complementary and Alternative Medicine and the Dietary Supplement Health and Education Act of 1994 hoped to undermine, they are low. The coronavirus has overturned the belief that vitamin D and vitamin C could prevent everything.
.
[ad_2]
Source link
